Reduced Expression of Erythropoietin After Intravitreal Ranibizumab in Proliferative Diabetic Retinopathy Patients—Retrospective Interventional Study

Reduced Expression of Erythropoietin After Intravitreal Ranibizumab in Proliferative Diabetic Retinopathy Patients—Retrospective Interventional Study

Purpose: To evaluate the expressions of erythropoietin (EPO) and vascular endothelial growth factor (VEGF) in the vitreous and fibrovascular membranes (FVMs) of proliferative diabetic retinopathy (PDR) after the intravitreal injection of ranibizumab (IVR) and further explore the relationship between...

Full description

Bibliographic Details
Main Authors: Li Chen, Jing Feng, Yanhong Shi, Fuxiao Luan, Fang Ma, Yingjie Wang, Weiqiang Yang, Yong Tao
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Medicine
Subjects:
erythropoietin
intraocular fluid
intravitreal ranibizumab
proliferative diabetic retinopathy (PDR)
vascular endothelial growth factor (VEGF)
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2021.710079/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2021.710079/full

Similar Items